Follow-up data extends to 2–3 years post-treatment in some cohorts. Clinical benefit typically emerges over weeks to months; inflammatory markers begin declining within 4–8 weeks. Durability appears dose-dependent—single infusions show shorter windows (4–8 months), while multi-dose protocols sustain improvements longer. Repeat treatments may be necessary every 1–2 years if relapse occurs.
Lupus (systemic lupus erythematosus, SLE) is an autoimmune disease in which the body's immune system mistakenly attacks its own tissues, particularly affecting joints, skin, kidneys, and the nervous system. The condition arises when B cells and T cells lose tolerance to self-antigens, producing damaging antibodies and inflammatory cytokines. Placental mesenchymal stem cells show promise because they release immunomodulatory factors—interleukins, soluble HLA-G, and exosomes containing regulatory microRNAs—that rebalance Th17 and regulatory T-cell populations. Early-stage clinical research (47 registered trials, 6 currently recruiting) suggests this approach may reduce disease activity scores and improve organ function in selected patients, though long-term remission rates remain under investigation.
Am I a candidate? → · Lupus (SLE): full overview → · Lupus (SLE) cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Médecine régénérative certifiée GMP au cœur de l'UE — à partir de 3 000–8 000 €, une fraction des prix américains ou allemands. Protocoles personnalisés pour patients de plus de 50 pays.
Évaluation médicale gratuite